Fountain Life’s Post

Watch and listen to Peter H. Diamandis!

Is your portfolio prepared to navigate the upcoming trends of Q3? As economic growth remains robust, driven by sectors like defense, AI, and obesity drug manufacturing, this Q3 outlook is all about the fragility of this "sandcastle economy". Dive into the complexities of our current economic landscape and prepare for potential challenges ahead with this quarterly outlook: https://lnkd.in/dTaqAUyn Visit: home.saxo #Saxo #BeInvested #QuarterlyOutlook

Is your portfolio prepared to navigate the upcoming trends of Q3?   As economic growth remains robust, driven by sectors like defense, AI, and obesity drug manufacturing, this Q3 outlook is all about the fragility of this "sandcastle economy".   Dive into the complexities of our current economic landscape and prepare for potential challenges ahead with this quarterly outlook: https://lnkd.in/gCuf7pzV   #Saxo #BeInvested #QuarterlyOutlook

"What we have seen is just the beginning, never again will technological innovations move as slow as it is moving today" (Antonio Guterres- UN Secretary General) How can we close the gap between technology and society? What lessons can we learn from our societies' experience with AI to apply to quantum computing and gene editing? Intellectia Advisors connecting science and society. https://lnkd.in/gsgpSRy2

The life sciences industry is seeing revolutionary advancements despite continued macroeconomic pressures. How will the industry fare in 2024? Find out in our latest report: https://cbre.co/3NWENWC #LifeSciences

Genetic Analysis AS offer of approx. NOK 9 million is ongoing. Shareholders are hereby invited to subscribe for shares with preferential right. Acquired subscription rights give the same right to subscribe for shares in the offer. The subscription period ends on December 22, 2023. Supplying high quality diagnostics to the microbiome market Genetic Analysis has spent several years within research in the microbiome field and has developed the patented GA-map® platform that includes advanced algorithms that immediately compare the patient’s microbiome results with a healthy reference population. The Company currently provides and sells three GA-map® products, one targeting the area of IBS/IBD, one for detection of COVID-19 in the gut, and one product targeted for research and exploratory work. Why invest in Genetic Analysis? ·        Gut health is a crucial factor for human well-being ·        Health benefits for patients and society ·        Genetic Analysis is at the microbiome frontier Learn more about Genetic Analysis on their digital capital markets day on December 12, 2023, at 10:00 (CET). The event can be reached here:https://lnkd.in/dinDMhGe Read more about the offer and how to subscribe: https://lnkd.in/dvrfCUbK

Get ready to explore key #market trends, growth predictions, major players, and untapped opportunities. Whether you're an entrepreneur, investor, or industry expert, you'll find our meticulously researched data and in-depth analysis indispensable. Here's your chance to stay ahead of the curve, foresee trends, and make data-driven decisions! . Explore more @ https://lnkd.in/gsmzAXgV #DigitalHealth #HealthTech #EPharmacy #Insights #BusinessStrategy #ariztonresearchreveals

"Neuralink, Elon Musk’s brain-chip startup, implanted its first device in a human patient. Mr Musk said that initial results showed “promising neuron spike detection”. The implant, named Telepathy, seeks to help individuals control electronic devices using their thoughts. The technology is not new. Some of Neuralink’s competitors, such as Blackrock Neurotech, have already implanted many chips in human brains." Continued advancements in brain-chip technology, such as improved performance, reliability, and compatibility, could enhance their appeal and utility, driving further adoption. Especially if begins to give mental and physical advantages to those who get implants. However, this remains uncharted territory, with our ability to foresee the future limited. Question 1: Should we allow these alternate and simultaneous evolutions of man and machine to proceed? Question 2: Or perhaps the more pertinent question is "whether it's even possible to halt such technological progress?" It's possible that we may have already missed the opportunity to address the former question in a timely manner. Rest is in the hands of Godd?

Check out our most recent weekly #MarketCommentary titled "Impact of Tech Companies on the S&P 500"! https://lnkd.in/ggiBi744 #MilestoneWM #WealthManagement #Economy #Market #Insights